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Abstract
Background: The aim of this study was to examine the relationship between pulmonary exacerbations and
physical activity (PA) in adults with cystic fibrosis (CF).
Methods: We grouped adults with CF according to their exacerbation status in the year before study enrolment:
(1) <1 exacerbation/year; (2) 1–2 exacerbations/year; and (3) >2 exacerbations/year. PA was assessed objectively by
means of an accelerometer at the time of study enrolment.
Results: Patients with >2 exacerbations/year spent less time in PA; specifically, fewer activities of mild intensity [>3
metabolic equivalents (METs)], and lower active energy expenditure (P = 0.01 and P = 0.03, respectively). After
correcting for relevant confounders, PA levels were not related to the exacerbation frequency in the preceding year.
PA at moderate intensity (4.8–7.2 METs) or greater (>7.2 METs) was independently associated with gender and FEV1
% predicted (P = 0.007 and P = 0.04, respectively). Compared with men, women had reduced vigorous activities
(P = 0.01) and active energy expenditure (P = 0.01).
Conclusions: Adult CF patients with more pulmonary exacerbations in the preceding year have more advanced
disease and are less active than their peers. PA was independently associated with gender and airflow obstruction.
Gender differences in PA are evident in CF adults.
Keywords: Daily physical activity, Pulmonary exacerbation rates, Cystic fibrosis, Gender difference
Background
Despite many new therapies emerging in cystic fibrosis
(CF) [1], lung disease is still the major source of morbid-
ity and mortality for patients with CF [2]. One of the
hallmarks of CF lung disease is the recurrence of pul-
monary exacerbations that are associated with mortality
risk [3], skeletal muscle weakness [4], reduced quality of
life [5], and higher health care costs [6]. Many authors
have examined the effect of pulmonary exacerbations on
lung function [7, 8] and have demonstrated that up to
one-third of CF patients will not recover their baseline
forced expiratory volume in 1 s (FEV1) [7]. Recently, a
large group of CF young adults were followed for
~7 years, and half of the decline in FEV1 was associated
with severe pulmonary exacerbations requiring hospital-
isation and intravenous antibiotics [9]. The authors
agreed with previous studies confirming that three exac-
erbations per year represent a crucial tipping point in
terms of lung function decline in CF [9, 10]. De Boer et
al. also demonstrated that CF patients with >2 exacerba-
tions/year have an increased 3-year risk of death or lung
transplantation [10].
There is now general agreement among CF health pro-
fessionals that physical activity improves sputum clearance
[11], pulmonary function [12] and muscle strength [13],
and it may influence inflammatory markers and immune
cell function [14]. There is also evidence about the physio-
logical effects of exercise and the mechanisms by which
exercise may improve important clinical outcomes in CF,
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such as exercise tolerance [15, 16], bone mineral density,
CF-related diabetes, and quality of life [17].
Several studies involving CF patients have monitored
physical activity during acute pulmonary exacerbation.
They have shown that activity levels are lower in pa-
tients with acute pulmonary exacerbation compared with
stable controls [13], and that energy expenditure is re-
duced during hospitalisation for respiratory exacerbation
compared with 1 month post-discharge [4, 18]. To date,
the relationship between pulmonary exacerbation rate
and regular physical activity has not been well estab-
lished in clinically stable adults with CF. No study has
sought to understand the impact of frequency of pul-
monary exacerbations over 1 year on physical activity
levels. The possibility that more frequent pulmonary ex-
acerbations may lead to reduced regular physical activity
is worthy of further investigation.
Therefore, the purpose of this study was twofold: (1)
to examine the relationship between the number of pul-
monary exacerbations in the preceding year and physical
activity levels in a clinically stable adult CF population;
and (2) compare clinical characteristics and habitual
physical activity in adult men and women with CF.
Methods
Study design
A cohort of 60 adult patients with CF was recruited at
the Policlinico Umberto I Hospital, Sapienza University
of Rome, Italy and at the Royal Brompton Hospital,
London, UK. Data on pulmonary exacerbations in the
preceding 12-month period, demographic and clinical
characteristics, and daily physical activity levels were col-
lected at the time of enrolment. The study was approved
by the Ethics Committee of Policlinico Umberto I
Hospital, with approval number 582/11, and Royal
Brompton Hospital, protocol number 07/H0711/125.
Patients and data collection
Adult patients attending a CF outpatient clinic were
approached for participation in the study between
January 2012 and May 2014. Patients were included if
they were ≥18 years of age and had a confirmed diagno-
sis of CF based on genetic testing showing two CF-
causing mutations and/or two documented sweet
chloride values >60 mEq/L. Patients were excluded if
they had experienced a pulmonary exacerbation within
4 weeks of the study period; were on the waiting list for
lung transplantation; or had undergone lung transplant-
ation. Baseline data were collected at the time of study
entry.
After obtaining written informed consent and appro-
priate screening of medical history, we collected data on
age, sex, height, weight, body mass index (BMI), chronic
infections and CF comorbidity (pancreas insufficiency
and CF-related diabetes). We also collected information
on number of pulmonary exacerbations and exacerba-
tion treatment in the preceding 12-month period. Ex-
acerbation events were ascertained through a review of
electronic records and hospital charts. To check if there
were exacerbations that had not been captured in the
health records, direct patient interview was also con-
ducted. Specifically, we collected data on the number of
pulmonary exacerbations in the past year requiring oral
or intravenous antibiotics. Even if pulmonary exacerba-
tion remains a subjective diagnosis, and unifying defin-
ition is still lacking within the CF literature [19, 20],
pulmonary exacerbations were defined as acute or sub-
acute worsening of respiratory symptoms, severe enough
to warrant oral or intravenous antibiotics. Antibiotic
treatment was at the discretion of the treating physician.
All patients underwent pulmonary function testing at
the time of study entry, which was performed according
to American Thoracic Society (ATS) standards, and
expressed as percentages of predicted values [21].
Assessment of daily physical activity
Physical activity was assessed at the time of the study
enrolment, using a multi-sensor armband (SenseWear
Pro3 Armband; BodyMedia, Pittsburgh, PA, USA) that
the patients wore for at least 5 full consecutive days
when they were at home. Physical activity data were re-
corded for 5 full days for all patients and reported as the
average of 5 days.
The device was positioned on the upper right arm over
the triceps muscle at the midpoint between the acromion
and olecranon processes. Patients were instructed to wear
the armband day and night and only to remove it for bath-
ing or showering. Patients were also asked to continue any
respiratory medications and any of their normal activities.
The sensor contained a biaxial accelerometer, galvanic
skin response sensor, heat flux sensor, skin temperature
sensor, and a near-body ambient temperature sensor from
which the data were stored every minute. Using specific
software (version 6.1), these variables, as well as body
weight, height, handedness and smoking status (smoker or
non-smoker), were used to estimate energy expenditure
(EE). Several aspects of EE, including total energy expend-
iture (TEE) and active energy expenditure (AEE), were
also calculated. The intensity of physical activity,
expressed in metabolic equivalents (METs), total physical
activity duration, the number of steps, time lying down,
and sleep duration were also measured. The outputs ob-
tained from the armband were time spent in physical ac-
tivity at different intensities, and the definitions for
activity levels based on METs were those used by Troos-
ters et al. [16]. The time spent with an EE of 3–4.8 METs
was considered mild activity (e.g., walking at normal
speed, or carrying out light household work); time spent
Savi et al. BMC Pulmonary Medicine  (2015) 15:151 Page 2 of 7
at 4.8–7.2 METs was considered moderate activity (e.g.,
brisk walking or cycling); and activities with EE >7.2 METs
were considered vigorous (e.g., running or activity with
training effects when applied for a sufficient length of time
and at an appropriate training frequency) [22]. Studies
performed in patients with CF have validated the use of
the SenseWear Armband and have shown that the hyper-
salinity of sweat does not affect the accuracy of EE estima-
tion, and have demonstrated that the device provides an
accurate estimate of physical activity in the free-living en-
vironment [23, 24]. Finally, it was reported in CF that
5 days monitoring was enough to assess habitual PA and
that PA levels were similar through the week (i.e., week-
days versus weekend days) [15, 16].
Statistical analysis
Baseline characteristics of the group were obtained on
the day of enrolment. Patients were grouped according
to their exacerbation status in the preceding year: (1) <1
exacerbation/year; (2) 1–2 exacerbations/year; and (3) >2
exacerbations/year. The groupings were made a priori
before commencing study analysis, based on data in the
literature [10]. We selected three exacerbation groups to
determine if there was different daily activity related to
pulmonary exacerbation frequency. Once established,
the exacerbation groupings were used as predefined
thresholds and subsequent analysis were performed
using these thresholds.
Categorical data are presented as percentages, and
comparisons were performed using the χ2 or Fisher’s
exact test. Male and female patients were compared
using an unpaired t test.
Parametric data are presented as mean ± standard
deviation (SD) and comparisons were made using the
two-sample independent t test or one-way analysis of
variance (ANOVA). Non-parametric data are pre-
sented as median and interquartile range and compar-
isons were performed using the Mann–Whitney or
Kruskal–Wallis test.
Physical activity variables, age, sex, BMI, FEV1
expressed as percentage of predicted (FEV1% predicted),
genotype, CF comorbidity (diabetes and pancreatic insuf-
ficiency) and infection with Pseudomonas aeruginosa
were compared among pulmonary exacerbation groups,
using statistical parametric and non-parametric tests and
a multivariate model (ANOVA).
All statistical tests were two-sided, and significance
was reported at P < 0.05.
Results
Study population characteristics and daily physical
activity
Baseline characteristics and pulmonary function data for
the group as a whole are shown in Table 1. A mean of
2.38 exacerbations per patient was reported: 2.92 in
women versus 2.0 in men, P = 0.13. Men were older than
women and had lower FEV1 % predicted (P = 0.04), while
women tended to have more exacerbations/year. Habit-
ual activity levels were significantly lower in women than
men (Table 2). Compared with men, women had reduced
TEE in daily life (P < 0.0001) and AEE (P = 0.01) and lower
average METs (P < 0.05). Activities with vigorous intensity
were lower in women (P = 0.01). Similarly, there was a
trend for less activity at moderate intensity [women 10
(6–24) min vs 19 (9–33) min for men; P = 0.16) and less
duration of physical activity (women 184 ± 115 min vs
233 ± 149 min for men, P = 0.17). After adjusting for other
covariates, these physical activity variables remained
significantly higher among male patients.
Association between pulmonary exacerbation and
physical activity
Eleven patients had <1 exacerbation/year, 31 had 1–2
exacerbations/years, and 18 had >2 exacerbations/year
(Table 3). The group with more frequent exacerbations
had a higher proportion of patients with a severe geno-
type (P = 0.001), pancreatic insufficiency (P = 0.006), CF-
related diabetes (P = 0.006), and had chronic P. aerugi-
nosa infection (P = 0.008). Patients who experienced >2
exacerbations/year had lower baseline FEV1; both
Table 1 Anthropometric characteristics and pulmonary function







Age, yr 33.5 ± 10.5 36.3 ± 11.0* 29.6 ± 7.6
BMI, Kg/ m2 23.1 ± 3.0 23.2 ± 2.7 23 ± 3.4
FEV1,L 2.59 ± 0.79 2.74 ± 0.88 2.37 ± 0.59
FEV1, % predicted 73.1 ± 19.9 68.8 ± 20.9* 71.9 ± 16.8
FVC, L 3.80 ± 1.00 4.22 ± 1.08* 3.22 ± 0.54
FVC, %predicted 90.0 ± 18.0 88.0 ± 21.7 93.3 ± 12.2
TLC, % predicted 98.5 ± 18.8 93.9 ± 19.8* 105.0 ± 15.0
DLCO, % predicted 83.9 ± 15.5 84.6 ± 17.1 82.9 ± 13.3
Pseudomonas aeruginosa
colonization, n (%)
39 (65) 24 (68.5) 15 (60)
Staphylococcus aureus
colonization, n (%)
41 (68.3) 26 (74.2) 15 (60)
Burkholderia cepacia colonization,
n (%)
2 (3.3) 2 (5.7) 0 (0)
Pancreatic insufficiency, n (%) 40 (66.6) 23 (65.7) 17 (68)




Number of exacerbations/year 2.38 ± 2.36 2.00 ± 1.69 2.92 ± 3.00
Data are presented as mean ± SD, unless otherwise stated
DLCO diffusion capacity of the lung for carbon monoxide; FVC forced vital
capacity; TLC total lung capacity
*P < 0.05, differences between men and women with CF
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Table 2 Daily physical activities measured by the accelerometer in 60 patients with CF
Variable CF (n = 60) Males (n = 35) Females (n = 25)
Total energy expenditure, kcal 2710 ± 592 2957 (2542–3217)* 2309 (2114–2524)
Active Energy expenditure, kcal 899 ± 602 830 (508–1562)* 617 (385–856)
Steps, number/day 9508 ± 3861 9984 ± 4246 8842 ± 3213
Duration Physical Activity, min/day 213 ± 137 233 ± 149 184 ± 115
Average METs 1.7 ± 0.3 1.8 ± 0.3* 1.6 ± 0.2
Mild intensity activities, min/day 186 ± 121 199 ± 129 168 ± 110
Moderate intensity activities, min/day 15 (9–29) 19 (9–33) 10 (6–24)
Vigorous intensity activities, min/day 1 (0–3) 1 (0–5) * 0 (0–0)
Data are presented as mean ± SD or median and interquartile range, unless otherwise stated
*P < 0.05, differences between men and women with CF
Table 3 Demographic characteristics of the whole group of 60 patients based on the exacerbation frequency
<1Exacerbation/year n = 11 1-2 Exacerbations/year n = 31 >2 Exacerbations/year n = 18 Between-group p value
Male/Female 7/4 19/12 9/9 0.68
Age, yr 32.5 ± 11.9 34.2 ± 10.2 33 ± 9.7 0.86
BMI, Kg/ m2 23.3 ± 3.4 22.6 ± 2.8 23.9 ± 3.1 0.33
508 del homozygous/
heterozygous
0/10 8/16 6/7 0.001
Pancreatic insufficiency, n (%) 3 (27.2) 22 (70.9) 15 (83.3) 0.006
CF-related diabetes, n (%) 1 (9.1) 4 (12.9) 9 (50) 0.006
Lung function
FEV1,L 3.09 ± 0.77 2.6 ± 0.73 2.25 ± 0.75 0.01
FEV1, % predicted 85 ± 22 72.5 ± 16 66.9 ± 21.8 0.05
FVC, L 4.2 ± 1.1 3.8 ± 0.97 3.4 ± 0.9 0.14
FVC, %predicted 97.3 ± 21.7 89.8 ± 16.2 86.5 ± 19.7 0.31
Chronic infections, n (%)
Pseudomonas aeruginosa 3 (27.2) 21 (67.7) 15 (83.3) 0.008
Staphylococcus aureus 9 (81.8) 24 (77.4) 9 (50) 0.1
Burkholderia cepacia 0 (0) 1 (3.2) 1 (5.5) 1
Daily physical activity
Total energy expenditure, kcal 2701.3 ± 706.7 2793.2 ± 631.9 2570.6 ± 428.4 0.45
Active energy expenditure, kcal 638 (349–699) 1003 (550–1377) 606.5 (464–752) 0.03
Steps, number/day 9449 ± 4981 10394 ± 3923 8018 ± 2492 0.11
Duration physical activity,
min/day
142 (80–225) 262 (159–327) 135.5 (85–182) 0.01
Average METs 1.6 (1.5–1.9) 1.8 (1.6–2.1) 1.6 (1.5–1.8) 0.01
Mild intensity activities,
min/day
126 (72–219) 213 (127–310) 119.5 (81–167) 0.01
Moderate intensity activities,
min/day
9 (5–21) 19 (9–38) 14.5 (6–26) 0.3
Vigorous intensity activities,
min/day
1 (0–2) 0 (0–4) 1 (0–2) 0.88
Data are presented as mean ± SD or median and interquartile range, unless otherwise stated
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expressed as absolute values and % of predicted (P = 0.01
and P = 0.05, respectively). As shown in Table 3, com-
pared with patients who had <1 or 1–2 exacerbations/
year, the group with >2 exacerbations/year spent less
time in daily physical activity (P = 0.01). Daily activities
at mild intensity were markedly reduced in patients with
>2 exacerbations/year (P = 0.01). AEE (i.e., number of
calories per day due to physical activity) and average
METs were lower in the group with more frequent exac-
erbations (P = 0.03 and P = 0.01, respectively). Con-
versely, there was no significant difference for activities
with at least moderate and vigorous intensity among the
three groups (Table 3).
There was however, no association between the num-
ber of pulmonary exacerbations in the preceding year
and physical activity variables when corrected for clinical
covariates (age, sex, BMI, FEV1% predicted, infection
with P. aeruginosa, genotype, diabetes and pancreatic in-
sufficiency). Daily physical activity was independently as-
sociated with gender and airflow obstruction. TEE and
AEE were related to sex (P < 0.0001 and P = 0.01, re-
spectively). Physical activities above the threshold of
moderate (4.8–7.2 METs) and vigorous (>7.2 METs) in-
tensity were also related to sex and FEV1% predicted (P =
0.007 and P = 0.04, respectively). Finally, the number of
steps was lower in those with a lower FEV1% predicted, al-
though this was not significant (P = 0.09).
Discussion
This study suggests that adult CF patients with more
pulmonary exacerbations in the preceding year have
more advanced disease and are less active than their
peers. After correcting for lung function and anthropo-
metric variables, there was no independent relationship
between pulmonary exacerbation frequency and daily
physical activities. In the present study, the level of phys-
ical activity was independently related to gender and air-
flow obstruction (FEV1% predicted). This indicates that
other factors rather than pulmonary exacerbation rate
contribute to the reduced habitual physical activity in a
period of clinical stability. Our results confirm that adult
women with CF are significantly less active than their
male counterparts and they tend to have more exacerba-
tions per year.
Unfortunately, despite developments in CF manage-
ment, pulmonary exacerbations continue to be one of
the hallmarks of CF lung disease, and the annual preva-
lence of pulmonary exacerbations increases with age [2].
Our study shows for the first time that patients with >2
exacerbations in the preceding year have a lifestyle char-
acterised by lower daily physical activity (including activ-
ities with mild, moderate and vigorous intensity) and
lower AEE compared with patients with fewer exacerba-
tions. This is also the first population-based cohort study
showing that physical activity at mild intensity level (e.g.,
walking at normal speed or shopping, and carrying out
light household work) is significantly reduced among pa-
tients with frequent exacerbation. Moreover, we found
that patients with frequent pulmonary exacerbations in
the preceding year were more likely to have diabetes, in-
fection with P. aeruginosa, and have lower lung function.
This is not surprising, and our data are in line with other
studies in which patients with frequent exacerbation
were diabetic, female and had more rapid decline in
FEV1 from baseline compared with those with infre-
quent exacerbation [10]. Diabetes, P. aeruginosa infec-
tion and reduced FEV1 are known risk factors for
pulmonary exacerbations in CF [25]. The novelty of our
study is that patients with >2 exacerbations in the past
year also have reduced daily physical activity. Even with
a prospective study design, it is difficult to infer causality
and whether the inactivity aggravated the decline of
FEV1, inhibited diabetes control, and trigged more exac-
erbations. In order to assess causality, the effect of inter-
ventions aimed at enhancing habitual physical activity
should be studied.
Patients with <1 exacerbation/year had less comorbid-
ity and better lung function but were more sedentary
compared with those with 1–2 exacerbations/year for all
the parameters measured by the accelerometer. Specific-
ally, regarding physical activity levels at moderate inten-
sity, the CF group with <1 exacerbation/year was less
active than those with more exacerbations. Duration of
moderate activities was 9 min in patients with <1 exacer-
bation/year, 19 min in those with 1–2 exacerbations/year
and 14.5 min in those with >2 exacerbations/year. It is
possible that the differences in the moderate activity re-
sults reflect motivation to participate in the study; are
related to sampling error (i.e., small number of patients);
or related to greater encouragement to exercise as a con-
sequence of more frequent healthcare interaction.
Having adjusted for baseline clinical covariates, we
observed that there was no independent relationship
between the number of pulmonary exacerbations in
the previous year and physical activity variables. Any
conclusion about causal links between exacerbations
and habitual physical activity must therefore be lim-
ited. The two most important determinants of phys-
ical activity variability in the present study were
gender and FEV1% predicted.
We found that daily activity at moderate intensity or
greater and EE were independently associated with sex,
with higher values among male patients. When gender
was evaluated separately, adult women with CF were
significantly less active than their male counterparts,
even when adjusted for previously mentioned covari-
ates. Although some physical activity parameters only
tended to be higher among men, these results still have
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significant clinical relevance. Similar gender differences
in habitual physical activity have previously been shown
in a paediatric CF population [26, 27]. Our study is the
first to demonstrate that this carries over to adulthood,
using an objective measurement. We have also noted a
trend for more exacerbations per year in women than
in men with CF.
It may be important to identify new strategies to im-
prove physical activity among women with CF who do
not voluntarily engage in their habitual daily life. Further
research is needed to determine whether strategies for
promotion of activity work equally for both sexes. There
is clearly a need to study a different approach to stimu-
late physical activity among women, considering that
gender differences in habitual activity are evident after
the onset of puberty [27]. Recently, Cox et al. [28] have
emphasised the lack of evidence regarding the most ef-
fective strategies to promote uptake and continued par-
ticipation in physical activity for CF patients. We believe
that activities of mild intensity (e.g., walking around the
home or office, shopping, and walking from the parking
lot) are simple behaviours that could be easily advised at
any medical encounter with CF patients and incorpo-
rated into any management plan.
It is of note that a multivariate analysis identified
FEV1% predicted as an independent, statistically signifi-
cant predictor of physical activity above moderate inten-
sity. This would suggest that in stable CF patients, high
activity levels in daily life do reflect the level of lung
function. This is in line with previous observations that
aerobic performance is correlated with measures of lung
function [16, 29]. Our study underlines that, in this clin-
ically stable CF population, the time spent doing activ-
ities of moderate intensity or greater is positively related
to pulmonary function.
The study had some important limitations. First, we
showed that CF patients with >2 pulmonary exacerbations
in the past year were more sedentary compared with those
with less frequent exacerbations. Even with a prospective
study design for physical activity monitoring, it is not pos-
sible to infer direct causality from these observations, and
whether less physical activity occurred prior to the identi-
fication of the exacerbations or was a direct result of
several exacerbations. In fact, a request to conduct pro-
spectively planned cohort studies to provide a stronger
evidence base for determinants and outcomes of physical
activity was recently made to the research community
[30]. Interventional studies should test the efficacy and ef-
fectiveness of physical activity programmes in reducing
the individual annual rate of pulmonary exacerbations in
CF. The second limitation was the retrospective nature of
the data collection for pulmonary exacerbation rates,
which may have underestimated the rate of exacerbations.
Even if our CF patients were closely followed up and
exacerbation events were ascertained through a review of
electronic medical records and hospital charts, some mild
exacerbations may not have been recorded. Finally, there
was the definition of exacerbations. A single agreed defin-
ition of pulmonary exacerbations is lacking [19, 20] and
pulmonary exacerbations defined by change in treatment
(i.e., new oral or intravenous antibiotics) provides a prag-
matic definition used in other publications [9, 10].
Conclusions
Adults with CF who had >2 pulmonary exacerbations in
the year prior to physical exercise assessment had more
advanced disease and were less active than patients with
1–2 or < 1 exacerbation/year. Specifically, daily activities
at mild intensity were markedly reduced in patients with
frequent CF exacerbations. After correcting for relevant
confounders, the level of daily physical activity was not
related to the exacerbation frequency in the preceding
year, but it was independently associated with gender
and pulmonary obstruction. Gender differences in daily
physical activity are evident in adult patients with CF.
This study adds to the mounting evidence that, in clin-
ical practice, we should recommend the benefits of keep-
ing an active lifestyle that does not require huge effort
and can be incorporated into daily life easily, especially
for patients who are known to have frequent exacerba-
tions. These findings strengthen the evidence to support
the development of different strategies to promote regu-
lar physical exercise in women with CF. More research
is needed in CF to investigate the efficacy of exercise or
physical activity interventions on definitive clinical end-
points such as exacerbation rates and survival.
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